Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H1 2018

January 2018 | 74 pages | ID: G000580C8CFEN
Global Markets Direct

Abstracts

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H1 2018

SUMMARY

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha - Pipeline Review, H1 2018, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Granulocyte macrophage colony stimulating factor receptor subunit alpha also known as CD116 is a receptor for granulocyte macrophage colony-stimulating factor. It is a member of the cytokine family of receptors. It plays an important role in controls the production, differentiation, and function of granulocytes and macrophages. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 1 and 5 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Toxicology, Central Nervous System, Dermatology, Gastrointestinal, Hematological Disorders and Infectious Disease which include indications Melanoma, Colorectal Cancer, Lung Disease, Prostate Cancer, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Respiratory Distress Syndrome, Alzheimer's Disease, Appendicitis, Asthma, Chemotherapy Effects, Chemotherapy Induced Neutropenia, Chronic Obstructive Pulmonary Disease (COPD), Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Lung Infections, Lung Injury, Malignant Pleural Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Mild Cognitive Impairment, Multiple Myeloma (Kahler Disease), Neurology, Parkinson's Disease, Peritonitis, Radiation Induced Myelosuppression, Radiation Injury, Respiratory Syncytial Virus (RSV) Infections, Skin Ulcers and Wounds.

Furthermore, this report also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
• The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects
• The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Overview
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Companies Involved in Therapeutics Development
Aduro BioTech Inc
Bolder Biotechnology Inc
Genzyme Corp
Johnson & Johnson
OncBioMune Pharmaceuticals Inc
Pharmaxis Ltd
Profarma
Savara Inc
Targovax ASA
XL-protein GmbH
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Drug Profiles
BBT-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMJG-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GVAX Colorectal Cancer Vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GVAX Multiple Myeloma Vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GVAX Vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONCOS-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostatac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-2200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Discontinued Products
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Product Development Milestones
Featured News & Press Releases
Jan 10, 2018: 70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time
Jan 04, 2018: Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
Dec 21, 2017: One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
Dec 11, 2017: Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
Dec 05, 2017: 100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
Nov 13, 2017: 80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
Sep 14, 2017: OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
Sep 12, 2017: Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
Sep 11, 2017: Targovax: Abstract on ONCOS-102 has been presented at ESMO Conference
Aug 31, 2017: OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment
Aug 29, 2017: OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference
Aug 24, 2017: Final Patient Completes Treatment in OncBioMune Clinical Trial of ProscaVax for Prostate Cancer
Aug 23, 2017: Targovax ASA: Abstract on ONCOS-102 to be presented at the ESMO 2017 Congress
Jul 13, 2017: Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement
Jun 27, 2017: Enrollment to Begin in OncBioMunes Trial of ProscaVax for Prostate Cancer in Mexico
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aduro BioTech Inc, H1 2018
Pipeline by Bolder Biotechnology Inc, H1 2018
Pipeline by Genzyme Corp, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by OncBioMune Pharmaceuticals Inc, H1 2018
Pipeline by Pharmaxis Ltd, H1 2018
Pipeline by Profarma, H1 2018
Pipeline by Savara Inc, H1 2018
Pipeline by Targovax ASA, H1 2018
Pipeline by XL-protein GmbH, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Aduro BioTech Inc
Bolder Biotechnology Inc
Genzyme Corp
Johnson & Johnson
OncBioMune Pharmaceuticals Inc
Pharmaxis Ltd
Profarma
Savara Inc
Targovax ASA
XL-protein GmbH